Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Zenas Biopharma Inc (NASDAQ: ZBIO) was $15.2 for the day, down -8.49% from the previous closing price of $16.61. In other words, the price has decreased by -$8.49 from its previous closing price. On the day, 3.12 million shares were traded. ZBIO stock price reached its highest trading level at $16.145 during the session, while it also had its lowest trading level at $13.75.
Ratios:
Our analysis of ZBIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.66 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 20, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $35.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $19.Wolfe Research initiated its Outperform rating on February 04, 2025, with a $19 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 09 ’25 when Nunn Jason Raleigh bought 63,158 shares for $19.00 per share. The transaction valued at 1,200,002 led to the insider holds 1,173,395 shares of the business.
SR ONE CAPITAL MANAGEMENT, LLC bought 126,315 shares of ZBIO for $2,399,985 on Oct 09 ’25. The 10% Owner now owns 1,917,895 shares after completing the transaction at $19.00 per share. On Oct 09 ’25, another insider, ENRIGHT PATRICK G, who serves as the Director of the company, bought 105,265 shares for $19.00 each. As a result, the insider paid 2,000,035 and bolstered with 1,832,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBIO now has a Market Capitalization of 815923328 and an Enterprise Value of 525837312. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.39 while its Price-to-Book (P/B) ratio in mrq is 3.27. Its current Enterprise Value per Revenue stands at 35.056 whereas that against EBITDA is -2.688.
Stock Price History:
The Beta on a monthly basis for ZBIO is -1.26, which has changed by 0.78987074 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, ZBIO has reached a high of $44.60, while it has fallen to a 52-week low of $5.83. The 50-Day Moving Average of the stock is -56.65%, while the 200-Day Moving Average is calculated to be -21.56%.
Shares Statistics:
ZBIO traded an average of 566.55K shares per day over the past three months and 1187570 shares per day over the past ten days. A total of 42.21M shares are outstanding, with a floating share count of 21.93M. Insiders hold about 59.14% of the company’s shares, while institutions hold 31.11% stake in the company. Shares short for ZBIO as of 1765756800 were 4950866 with a Short Ratio of 8.74, compared to 1763078400 on 4607781. Therefore, it implies a Short% of Shares Outstanding of 4950866 and a Short% of Float of 12.3.
